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Nonresectable Hepatocellular Carcinoma: Long-term Toxicity in Patients Treated
with Transarterial Chemoembolization - Single-Center Experience
Abstract
Purpose
Purpose: To determine the toxicity profile of transarterial chemoembolization (TACE) at 6 months and 1
year after treatment in patients with hepatocellular carcinoma (HCC) in a standardized oncology protocol
so that TACE could be compared with systemic chemotherapeutic regimens for liver cancer.
Materials and Methods
Methods: The study was authorized by the institutional review board. Between January
2002 and January 2007, 190 patients (155 men, 35 women; median age, 65 years; age range, 18 – 84
years) with HCC who underwent TACE treatment were identified from a prospectively collected database.
Clinical records of complete blood cell counts and chemical profiles at baseline and at 6 and 12 months
after treatment were studied retrospectively. Toxicity was graded according to the common terminology
criteria for adverse events (CTCAE). A transition (survival) analysis perspective was used to estimate the
distribution of toxicity grades. Patient survival from the first TACE session was calculated with KaplanMeier analysis.
Results
Results: Grade 3 or 4 toxicity 6 and 12 months, respectively, after treatment included leukocytopenia (7%
and 19%); anemia (9% and 19%); thromobocytopenia (13% and 23%); prolonged activated partial
thromboplastin time (8% and 18%); elevated aspartate aminotransferase (15% and 18%), alanine
aminotransferase (10% and 18%), and alkaline phosphatase (8% and 18%) levels; hypoalbuminemia (10%
and 19%); hyperbilirubinemia (10% and 22%); and alopecia (18%). The cumulative survival rate was 58% at
1 year, 39% at 2 years, and 29% at 3 years. These toxicity rates were considerably lower than those
reported after treatment with currently used systemic chemotherapeutic agents.
Conclusion
Conclusion: Study results show that TACE has a favorable long-term toxicity profile in patients with HCC.
Data clearly support the role of TACE in the treatment of patients with nonresectable HHC.
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Purpose:

To determine the toxicity profile of transarterial chemoembolization (TACE) at 6 months and 1 year after treatment in patients with hepatocellular carcinoma (HCC) in a
standardized oncology protocol so that TACE could be
compared with systemic chemotherapeutic regimens for
liver cancer.

Materials and
Methods:

The study was authorized by the institutional review
board. Between January 2002 and January 2007, 190 patients (155 men, 35 women; median age, 65 years; age
range, 18 – 84 years) with HCC who underwent TACE
treatment were identified from a prospectively collected
database. Clinical records of complete blood cell counts
and chemical profiles at baseline and at 6 and 12 months
after treatment were studied retrospectively. Toxicity was
graded according to the common terminology criteria for
adverse events (CTCAE). A transition (survival) analysis
perspective was used to estimate the distribution of toxicity grades. Patient survival from the first TACE session
was calculated with Kaplan-Meier analysis.

Results:

Grade 3 or 4 toxicity 6 and 12 months, respectively, after
treatment included leukocytopenia (7% and 19%); anemia
(9% and 19%); thromobocytopenia (13% and 23%); prolonged activated partial thromboplastin time (8% and
18%); elevated aspartate aminotransferase (15% and
18%), alanine aminotransferase (10% and 18%), and alkaline phosphatase (8% and 18%) levels; hypoalbuminemia
(10% and 19%); hyperbilirubinemia (10% and 22%); and
alopecia (18%). The cumulative survival rate was 58% at 1
year, 39% at 2 years, and 29% at 3 years. These toxicity
rates were considerably lower than those reported after
treatment with currently used systemic chemotherapeutic
agents.

Conclusion:

Study results show that TACE has a favorable long-term
toxicity profile in patients with HCC. Data clearly support
the role of TACE in the treatment of patients with nonresectable HCC.
娀 RSNA, 2008
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H

epatocellular carcinoma (HCC)
is the fifth most common cancer
in the world (1). The incidence
of and mortality rate with HCC continue to rise steadily in North America
and Europe, mainly owing to the concomitant increase in hepatitis C viral
infections (2,3).
Surgical treatments, including hepatic resection, liver transplantation,
and percutaneous ablation, are considered the only curative treatments for
patients with early-stage HCC and yield
5-year survival rates of 50%–70% (4).
However, fewer than 20% of patients
with HCC can be treated surgically, and
given the lack of a survival benefit from
systemic chemotherapy, locoregional
therapeutic options such as transarterial chemoembolization (TACE) have
become the mainstay of therapy.
A key theoretic advantage of chemoembolization over systemic chemotherapy is that the chemotherapeutic agents
used (doxorubicin, cisplatin, and others) are not intravenously infused
throughout the systemic circulation;
rather, they are administered locally
through the hepatic artery. This is especially important in patients with HCC,
who also have underlying liver dysfunction. One of the main concerns regarding systemic chemotherapy is the fact
that patients who receive this form of
treatment may experience side effects
that include pain, nausea, vomiting, myelosuppresion, and alopecia and/or serious adverse events such as cardiac
toxicity. These side effects are well described in the Common Terminology
Criteria for Adverse Events (CTCAE),

Advance in Knowledge
䡲 The study results show that
transarterial chemoembolization
(TACE), as compared with systemically administered chemotherapeutic treatments, has a favorable toxicity profile in patients
with hepatocellular carcinoma
(HCC), with minimal long-term
toxicities, and the data clearly
support the role of TACE in the
treatment of patients with nonresectable HCC.
Radiology: Volume 249: Number 1—October 2008

version 3.0 (5), and represent one of
the major disadvantages of using systemically delivered chemotherapy.
Moreover, rates of response to single or
combination chemotherapy are still
very low—typically less than 20% (6).
The subjectively reported side effects of TACE are mild compared with
those caused by systemic chemotherapy. These side effects are in large part
attributed to postembolization syndrome and include nausea, vomiting,
abdominal pain, fever, and loss of appetite (7,8). Because the focus of most
studies is patient survival rather than
toxicities caused by TACE, precise analysis of potential TACE-induced systemic
toxicities is lacking (9,10).
Yet the potential lack of severe systemic toxicities after TACE compared
with those after systemic chemotherapy
is one of the most important advantages
of using this locoregional therapeutic approach. Therefore, the goal of our study
was to determine the toxicity profile of
TACE at 6 months and 1 year after treatment in patients with HCC in a standardized oncology protocol (CTCAE, version
3.0) so that TACE could be compared
with the use of the systemic chemotherapeutic agents most commonly used for
liver cancer (ie, doxorubicin, cisplatin,
and 5-fluorouracil).
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of these patients, the diagnosis of HCC
was based on either the findings in
histologic specimens obtained with
needle biopsy or the finding of a hypervascular lesion on cross-sectional
magnetic resonance (MR) images in
addition to an ␣-fetoprotein level
higher than 400 U/L (400 g/L). Only
those patients who were not suitable
for curative therapies such as resection, liver transplantation, or percutaneous intervention were considered
for TACE. Patients were required to
be at least 18 years old, have preserved liver function (Child-Pugh class
A or B) without substantial liver decompensation, and have an Eastern
Cooperative Oncology Group performance status score of 0 –2. Encephalopathy, severe variceal bleeding,
and/or either ascites, marked thrombocytopenia, prolonged impaired renal function, acute renal failure, or severe liver failure was considered an
absolute contraindication to TACE. All
patients provided written informed
consent before undergoing any studyspecific procedures. Only those patients whose baseline evaluation was
performed at our institution were included. Baseline evaluation included
complete blood cell count, a biochemical profile, and dynamic MR imaging.

Materials and Methods
Patient Selection
The study was authorized by the institutional review board of Johns Hopkins Hospital. We retrospectively analyzed prospectively collected data on
all patients with HCC who were evaluated at Johns Hopkins Hospital Liver
Clinic for possible TACE between January 1, 2002, and January 1, 2007. For all
Implication for Patient Care
䡲 Systemic toxicity is a well-known
disadvantage of chemotherapy;
our results give clinicians a good
overview of the toxicities that can
be expected after TACE and
therefore will be helpful for optimizing treatment strategies.
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Chemoembolization Technique
All chemoembolizations were performed
by a single experienced interventional
radiologist (J.F.H.G., K.H., C.S.G.)
and by using the same technique. An
18-gauge single-wall needle was used
with the Seldinger technique to access
the right common femoral artery. A
5-F vascular sheath was placed in the
right common femoral artery over a
0.035-inch guidewire (Terumo Medical, Somerset, NJ). With fluoroscopic
guidance, a 5-F glide Simmons-1 catheter (Cordis, Miami, Fla) was advanced into the aortic arch and then
used to select the celiac axis. The catheter was advanced over the guidewire
and into the desired hepatic artery
branch, depending on the tumor location. Selective catheterization was
performed to achieve lobar or segmental embolization based on the targeted lesions. A solution containing
100 mg of cisplatin (Platinol; BristolMyers Squibb, Princeton, NJ), 50 mg
of doxorubicin (Adriamycin; Pharmacia-Upjohn, Kalamazoo, Mich), and 10
mg of mitomycin C (Mutamycin C;
Bedford Laboratories, Bedford, Ohio)
in a 1:1 mixture with iodized oil was
infused and followed by the infusion of
either polyvinyl alcohol particles or
gelatin-coated trisacryl microspheres
(Embosphere particles; Biosphere
Medical, Rockland, Mass) until stasis
was achieved.

grade 1–5 toxicities, with unique clinical descriptions of the severity for
each adverse event (AE) based on the
following general guidelines: Grade 1
indicates mild AE; grade 2, moderate
AE; grade 3, severe AE; grade 4, lifethreatening or disabling AE; and grade
5, death related to AE. At the time of
analysis, the survival statuses of all
patients were obtained from the Social
Security Death Index. A decision was
also made to exclude from the analysis
any measurements that had been obtained within 3 weeks after TACE.
This decision was based on the fact
that transient transaminase elevation
is a normal response to TACE (without clinical consequences) that is seen
in nearly all patients who undergo this
treatment.
Typically, up to three separate
TACE treatments are performed in a
treatment cycle, similar to systemic
chemotherapy cycles. The decision to
repeat treatment was based on residual
enhancement seen at MR imaging. We
chose two time points at which to analyze the data: 6 months after the first
TACE for evaluation of short-term toxicity after a complete TACE cycle and 1
year after TACE for assessment of the
long-term effect of TACE on systemic
and liver-specific toxicities. These time
points also allowed us to compare our
results with those obtained with other
liver chemotherapy regimens.

Collected Data and Follow-up
According to the protocol, patients
underwent contrast material– enhanced and diffusion MR imaging 4 – 6
weeks after TACE for assessment of
tumor response. Complete blood cell
counts and biochemistry profiles were
acquired to assess toxicity. Patients
with nearly complete tumor necrosis
were followed up with MR imaging,
complete blood cell counts, and biochemistry profiles every 6 – 8 weeks.
Patients with residual enhancement
and a maintained clinical performance
status underwent additional TACE
treatment(s). Toxicity was assessed
and graded according to the CTCAE,
version 3.0, for toxicities. The CTCAE, version 3.0, are used to define

Statistical Analyses
The goal of our analysis was to estimate
the distribution of toxicity grades at
6-month and 1-year follow-up after the
first TACE. In the following paragraph,
we discuss the methods that we used to
estimate the toxicity distributions for
one value at the 6 month follow-up, as
these distributions are analogous for all
toxicity substances and both follow-up
times.
For the patients in whom toxicity
measurements were obtained both before and after 6 months, the closest measurements were used to obtain interpolated grades of toxicity at 6 months. For
patients who were alive but in whom
measurements had stopped before 6
months had passed, interpolation was not

348

Buijs et al

possible. To estimate the goal under reasonable assumptions, we viewed the
problem from a transition—that is, survival analysis—perspective. From this
perspective, for each patient, i, there are
six transition times—T0,i, T1,i, T2,i, T3,i,
T4,i, and Tdeath,i—that start from the first
TACE and end at the time (closest to 6
months) at which the patient transitions
to toxicity grade 0, to grade 1, to grade 2,
to grade 3, to grade 4, and to death, respectively. From this perspective, the
early stopping of measurements before 6
months is expressed as a censoring of
some transition times. For example, if the
last toxicity measurement in a patient was
obtained at 4 months and was grade 3,
then times T4,i and Tdeath,i are censored
at 4 months, whereas the times T3,i, T2,i,
T1,i, and T0,i are uncensored and can be
determined by tracing back the patient’s
measurements.
Details of the procedure used to
transform the original data to such
censored transition data are given in
the Appendix. For each grade g, we
estimated the fraction of patients (Pr)
for whom the transition time to grade
g, (Tg,i), was longer than 6 months,
Pr(Tg,i ⬎ 6 m), by using survival analysis methods that account for censoring (see below). Finally, assuming that
for the unobserved toxicity grades
within a period close to 6 months or 1
year toxicity does not decrease, our
goal—to determine the fraction of patients who were at a particular toxicity
grade at 6 months, Pr(g6m)— could be
achieved by using our estimates of
Pr(Tg,i ⬎ 6 m) according to the following formula:

Pr(g6m)
⫽ Pr(Tg,i ⱕ 6 m) ⫺ Pr(Tg⫹1,i ⱕ 6 m)
⫽[1 ⫺ Pr(Tg,i ⬎ 6 m)]
⫺ [1⫺Pr(Tg⫹1,i ⬎ 6 m)].
In other words, patients who were
at toxicity grade g at 6 months are
those patients who had transitioned to
grade g on or before the sixth month
(Tg,i ⱕ 6 m) but had not transitioned
to grade g ⫹ 1 on or before the sixth
month (Tg⫹1,i ⱕ 6 m). Because the
Radiology: Volume 249: Number 1—October 2008
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baseline toxicity grade can be predictive of both the transition times and
the censoring rates, we first estimated
Pr(Tg,i ⬎ 6 m) within strata of baseline
grades by using the within-strata
Kaplan-Meier estimator (11). Then
we reweighted these estimators according to the baseline grade distribution. We estimated baseline distributions of toxicity grades, transition distributions (see equation) within strata
of baseline grades for 6 months and 1
year, and overall transition distributions.

Results
Patient Characteristics
At analysis of the information in our database, we identified a total of 190 patients. The diagnosis of HCC was confirmed at histologic examination in 126
(66%) patients. The diagnosis of HCC in
the remaining 64 patients was based on
cross-sectional MR imaging findings and
elevated serum ␣-fetoprotein levels. Pa-

Patient Characteristics
Characteristic
No. of patients
Patient age (y)*
Male patients
Female patients
Race
White
African-American
Asian
Child-Pugh class
A
B
C
Hepatitis B
Hepatitis C
Diagnosis method
Histology
AFP level and MR imaging
findings
Multiple lesions
One lesion

Value
190
65 ⫾ 14
155 (82)
35 (18)
136 (72)
28 (15)
26 (14)
126 (66)
64 (34)
0
40 (21)
76 (40)
126 (66)
64 (34)
141 (74)
49 (26)

Note.—All except age data are numbers of patients,
with percentages in parentheses. AFP ⫽ ␣-fetoprotein.
* Mean age ⫾ standard deviation.
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tient characteristics are shown in the Table. There were 155 male and 35 female
patients (mean age, 65 years; age range,
18 – 84 years), and most of them (72%)
were white. Forty patients had chronic
hepatitis B, and 76 had chronic hepatitis
C. The majority of patients (66%) had
Child-Pugh class A cirrhosis. One hundred forty-one patients had multiple liver
tumors. The average number of TACE
sessions performed per patient was 2.4
(range, 1–3).

Hematologic Toxicity
The hematologic values observed in the
190 patients at baseline and 1 year after
TACE were graded according to the
CTCAE, version 3.0, and are presented
in Figure 1. Leukocytopenia, anemia,
thrombocytopenia, and prolonged activated partial thromboplastin time were
the most common hematologic toxic effects. For most patients, the observed
toxicity was mild (grade 1 or 2). Grade
3 and grade 4 leukocytopenia was detected in 6% and 1% of the patients,
respectively, after 6 months and in 6%
and 13% of the patients, respectively,
after 1 year. Grade 3 and grade 4 anemia was detected in 6% and 3% of the
patients, respectively, after 6 months
and in 4% and 15% of the patients,
respectively, after 1 year. Grade 3 and
grade 4 thrombocytopenia was detected
in 10% and 3% of the patients, respectively, after 6 months and in 8% and
15% of the patients, respectively, after
1 year. Grade 3 prolonged activated
partial thromboplastin time was detected in 8% of the patients after 6
months and in 18% of the patients after
1 year.
To assess the assumption that within a
period close to 6 months or 1 year after
TACE toxicity generally does not decrease, for each toxicity type we assessed
the data for all patients with measurements obtained both before and after 6
months— or before and after 1 year—and
thus in whom the assumption could be
tested. Among these patients, the percentages of patients with measurements
that were monotonic around 6 months
ranged from 87% (glucose) to 99% (creatinine); these proportions ranged from
83% (alanine aminotransferase) to 100%
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(creatinine) around 12 months, indicating
that our assumption was predominantly
valid for the data with which it could be
assessed.

Nonhematologic Toxicity
Postembolization syndrome consisting
of abdominal pain, fever, loss of appetite, and nausea developed in most patients. However, these symptoms
were generally mild and transient. Alopecia developed in 34 (18%) patients. Elevated aspartate aminotransferase, alanine aminotransferase, and
alkaline phosphatase levels; hypoalbuminemia; and hyperbilirubinemia
were frequent nonhematologic adverse effects (Fig 2). Grade 3 or 4
toxicity manifested as elevated aspartate aminotransferase levels in 15% of
the patients after 6 months and in 18%
after 1 year. Grade 3 or 4 alanine aminotransferase level elevations were
detected in 10% of the patients after 6
months and in 18% after 1 year.
Grade 3 alkaline phosphatase level elevations were detected in 8% of the
patients after 6 months and in 18%
after 1 year. Grade 3 hypoalbuminemia was detected in 10% of the patients after 6 months and in 19% after
1 year. Grade 3 or 4 total bilirubin
level elevation was detected in 10% of
the patients after 6 months and in 22%
after 1 year.
In our patient group, severe complications were rare. Acute liver failure occurred in five (2.6%) patients and led to
death in three of them. One patient died
of variceal bleeding within 1 month after
TACE. An intrahepatic abscess that developed in one patient 4 weeks after
TACE was managed with drainage. One
patient had a myocardial infarction 2 days
after TACE and was treated with coronary artery bypass graft surgery.
Survival
The data of all patients were included in
the survival analysis. Mean and median
survival times after diagnosis were 27 and
16 months, respectively. Cumulative survival rates were 58% at 1 year, 39%
at 2 years, and 29% at 3 years
(Fig 3). Survival analysis of data for the
126 patients with Child-Pugh class A
349
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Figure 1

Figure 1: Hematologic toxicities. Histograms show estimated distributions at baseline and at 1 year after first TACE in all 190 patients. Horizontal bar scales convey
the distributions of toxicity grades at baseline (bottom scale) and at 1 year (top scale). Vertical bars convey the possible associations between toxicity grades across the
two time points. aPTT ⫽ activated partial thromboplastin time, Hb ⫽ hemoglobin.

cirrhosis revealed cumulative survival
rates of 68% at 1 year, 44% at 2 years,
and 31% at 3 years.

Discussion
HCC is one of the most common fatal
cancers in the world. The incidence of
HCC in the United States is on the rise
owing to increased exposure to the hepatitis C virus (12). The prognosis is invariably poor, with a mean survival time
of 6 months (13). Unfortunately, only a
selected percentage of patients (10%–
15%) are candidates for curative therapies because of the advanced stage of
their disease at the time of diagnosis or
the presence of comorbidity (14). TACE
350

has become the mainstay of treatment
for patients with nonresectable HCC.
The aim in performing TACE is to deliver a high concentration of chemotherapeutic agents followed by an embolic
agent to the tumor. This embolization
blocks the arterial inflow and thus limits
the washout of drugs and reduces the
systemic side effects (15). Although this
is a widely accepted notion, to our
knowledge, there are no studies in the
literature to date in which the systemic
toxicities after TACE have been fully described. Therefore, our aim was to determine the toxicity profile of TACE in
patients at 6 months and 1 year after
treatment for HCC.
The results of several nonrandom-

ized trials have demonstrated the positive effect of TACE in terms of increased tumor necrosis, as well as the
improvements in patient survivals
(16,17). However, few controlled randomized studies have been published.
Early randomized clinical trials revealed
no survival benefit for patients with
HCC who were treated with TACE
(18,19). This can be explained by the
fact that in these early trials, either the
enrolled patients or the methods used for
TACE were heterogeneous. The two
most recent prospective randomized trials, however, revealed markedly longer
survivals after chemoembolization (9,10).
HCC is especially difficult to treat
with systemic chemotherapy, and alRadiology: Volume 249: Number 1—October 2008
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though multiple clinical trials have been
performed to test many single- and
combined-agent chemotherapies, to our
knowledge, no regimen has facilitated a
substantial tumor response or survival
benefit. Furthermore, systemic toxicity

is a well known disadvantage of chemotherapy. In fact, systemic toxicity is the
limiting factor in establishing the dose of
systemic chemotherapy, and in patients
with HCC, who are already compromised owing to underlying liver disease,

Buijs et al

such toxicity can be extremely dangerous (20,21). Sorafenib, an oral multikinase inhibitor, has induced partial tumor response; however, clinical trials
are still underway and an extensive toxicity profile has yet to be determined

Figure 2

Figure 2: Nonhematologic toxicities. Histograms show estimated distributions
at baseline and at 1 year after first TACE in all 190 patients. Horizontal bar scales
convey the distributions of toxicity grades at baseline (bottom scale) and at 1 year
(top scale). Vertical bars convey possible associations between toxicity grades
across the two time points. ALT ⫽ alanine aminotransferase, AST ⫽ aspartate aminotransferase.

Radiology: Volume 249: Number 1—October 2008

351

VASCULAR AND INTERVENTIONAL RADIOLOGY: Toxicity from Transarterial Chemoembolization

(22). We believe that locoregional therapy, such as TACE, is unique because it
delivers highly concentrated doses of
chemotherapy to the tumor in a specific
manner while preserving the nontumorous healthy liver tissue. In theory, this
should prevent the occurrence of major
systemic side effects.
The single chemotherapeutic agents
that have facilitated a consistent tumor
response rate of more than 10% are
doxorubicin, 5-fluorouracil, and cisplatin. These agents reportedly have induced hematologic toxicities in as high
as 22% of patients (grade 3 or 4 anemia), 28% of patients (grade 3 or 4
thrombocytopenia), and 67% of patients (grade 3 or 4 leukocytopenia)
(23). In comparison, our results confirm
the advantage of using locoregional
treatment: Grade 3 or 4 hematologic
toxicity manifesting as anemia, thrombocytopenia, or leukocytopenia was detected in only 9%, 13%, and 7% of the
patients 6 months after TACE, respectively. The reported median survival
time after systemic chemotherapy for
HCC is less than 6 months (range, 6 –20
weeks) (23). Our results indicate a median survival time of 16 months, and
hematologic toxicities manifesting as
leukocytopenia, anemia, thrombocytopenia, and prolonged activated partial
thromboplastin time were detected in
only 18%–23% of the patients after 1
year. Such results are even more remarkable given that all of these patients also
had evidence of cirrhosis and thus were
even more susceptible to the harmful
effects from chemotherapy. In the patients with hematologic toxicities, we
found no treatment-related mortalities,
whereas treatment-related death rates
as high as 25% have been reported in
patients treated with doxorubicin (24).
Alopecia is considered to be one of
the most distressing side effects of cancer therapy (25). This common side effect of systemic chemotherapy usually
occurs 2–3 weeks after the first cycle of
treatment. The likelihood of alopecia is
related to the type of drugs used and the
schedule of administration (26). Singledrug treatment with systemically administered anthracyclines leads to total
alopecia in approximately 90% of
352

treated patients (27). In our study, however, alopecia occurred in only 18% of
the patients treated with TACE. This
suggests that a substantial portion of the
locally delivered chemotherapeutic agent
in TACE stays in the tumor region. At
the very least, it appears that TACE
causes markedly lower rates of this
traumatic side effect than does systemic
chemotherapy.
Rarely, TACE induces hepatic failure that results in increased serum levels of aminotransferases and bilirubin,
ascites, or hepatic encephalopathy (28).
These adverse effects usually are transient, with liver function returning to
baseline levels within 3 weeks after
TACE— even in patients with advanced
HCC (but with Child-Pugh class A or B
cirrhosis). These effects are reportedly
independent of patient age, embolization site, and number of treatments
(29). In our patient population, grade 3
or 4 toxicities manifested as elevated
aminotransferase and bilirubin serum
levels in 18%–22% of the patients after
1 year. However, we cannot state conclusively whether this was a result of
TACE or a part of the natural progression of liver disease. Acute liver failure
occurred within 1 month after TACE in
2.6% of the patients and led to death in
1.6% of them.
Reported survival rates after TACE in
patients with HCC vary between 60% and
88% at 1 year, between 30% and 60% at
2 years, and between 18% and 50% at 3
years, depending on several risk factors,
such as Child-Pugh class, ␣-fetoprotein
level, and presence or absence of portal
vein thrombosis (30–32). In the present
study, survival rates were 58% at 1 year,
39% at 2 years, and 29% at 3 years; however, we did not stratify the patients for
potential risk factors. Portal vein thrombosis traditionally has been considered
one of the main contraindications to performing TACE (33). However, we previously reported that TACE can be performed safely in patients with this condition (34). Therefore, patients with
portal vein thrombosis were not excluded from this study. Moreover, 64
patients had baseline Child-Pugh class B
cirrhosis. The relative risk factors for
Child-Pugh class B cirrhosis (compared
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Figure 3

Figure 3: Overall survival curve for all 190
patients with nonresectable HCC who were treated
with TACE.

with Child-Pugh class A disease) and
portal vein thrombosis are reported to
be 1.72 and 1.58, respectively, and
therefore may influence survival rates
(35). The survival analysis of data for
the patients with Child-Pugh class A cirrhosis in our study revealed cumulative
survival rates of 68% at 1 year, 44% at
2 years, and 31% at 3 years.
This study had several limitations:
First, the study design was retrospective and not controlled. The uncontrolled nature of the study limited our
ability to compare our study outcomes
with those of other studies. However,
our endpoints were objective and were
obtained from a standardized source.
Second, for obvious ethical reasons, not
all patients underwent biopsy to confirm
the diagnosis of HCC. We believe that the
use of imaging features combined with
elevated ␣-fetoprotein levels is a well-established alternative for confirming the
diagnosis. Last, because it is difficult to
differentiate procedural toxicity from
progressive cirrhosis, our results represent findings in the worst-case scenario.
In conclusion, our results show
that TACE has a favorable toxicity
profile in patients with HCC, with minimal long-term toxicities. These data
clearly support the role of TACE in the
treatment of patients with nonresectable HCC. Our results give clinicians a
good overview of the toxicities that
can be expected after TACE and
Radiology: Volume 249: Number 1—October 2008
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thereby will be helpful for optimizing
treatment strategies.

Appendix
Below we describe in detail the procedure used to transform the original data
to censored transition data. We describe the procedure used to obtain the
transition data relevant for estimating
the proportion of patients whose toxicity grade at D months is larger than
grade g, Pr(Tg,i ⬎ D). There are two
main cases:

Case 1
In case 1, the patient has measurements
obtained both before and after the date
D. In this case, we define the measurement grade on the left or right of the interval, which includes date D as level.left or
level.right. Accordingly, time.left and
time.right are defined as the times when
these measurements are made. There
are two subcases. In subcase 1, the toxicity grade, g, increases around date D:
(a) If level.right is less than g, then the
transition data for the time to cross toxicity grade g (ie, time of follow-up and
observation status) are defined as (date
D ⫹ 1, 0). (b) If level.left is less than g
and level.right is greater than or equal
to g, then the transition data for the
time to cross toxicity grade g are defined as (crossing time, 1), where crossing time is the interpolated time between time.left and time.right for crossing g. (c) If both level.left and level.right
are greater than or equal to g, then the
transition data for the time to cross toxicity grade g are defined as (track back,
1), where track back is the first time the
grade crossed g.
In subcase 2, the toxicity grade either decreases or does not change
around date D: (a) If that grade is less
than g, then the transition data for the
time to cross toxicity grade g are (date
D ⫹ 1, 0). (b) Otherwise, the transition
data for the time to cross toxicity grade
g are (track back, 1).
Case 2
In case 2, there is no measurement after date D. In this case, level.left deRadiology: Volume 249: Number 1—October 2008

notes the second to the last measurement and level.right denotes the last
measurement. Accordingly, time.left
and time.right are defined. There are
three conditions: (a) If level.right is
less than g, then the transition data
are (time.right, 0). (b) If level.left is
less than g and level.right is greater
than or equal to g, then the transition
data are (crossing time, 1). (c) If both
level.left and level.right are greater
than or equal to g, then the transition
data are (track back, 1).
We provide an example: A patient
had a measurement of glucose toxicity
of grade 0 at 153 days, and the next
measurement was obtained at grade 2
at 226 days. This patient is predicted to
have crossed grade 2 at day 202; thus,
this patient’s contribution to estimating
the proportion of patients whose toxicity grade at 180 days has crossed grade
2, Pr(T2,i ⬎ 180 days), belongs in category 1(1)b (case 1, subcase 1, condition
b) and the transition data are (202, 1).
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